Japanese encephalitis future or investigational therapies
Japanese encephalitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Japanese encephalitis future or investigational therapies On the Web |
American Roentgen Ray Society Images of Japanese encephalitis future or investigational therapies |
FDA on Japanese encephalitis future or investigational therapies |
CDC on Japanese encephalitis future or investigational therapies |
Japanese encephalitis future or investigational therapies in the news |
Blogs on Japanese encephalitis future or investigational therapies |
Risk calculators and risk factors for Japanese encephalitis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
There are a number of new vaccines under development. The mouse-brain derived vaccine is likely to be replaced by a cell-culture derived vaccine that is both safer and cheaper to produce. China licensed a live attenuated vaccine in 1988 and more than 200 million doses have been given; this vaccine is available in Nepal, Sri Lanka, South Korea and India. There is also a new chimeric vaccine based on the yellow fever 17D vaccine that is currently under development[1].
References
- ↑ Tom Solomon (2006). "Control of Japanese Encephalitis—within our grasp?". 355 (9): 869–871.